Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With Rituximab ± Lenalidomide in Untreated MZL
NCT07448324Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete Response Rate at cycle 12. Started Apr 2025; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07448324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448324.